Enalare Therapeutics Completes Formation of Its Scientific Advisory Board Posted Jan 13, 2021
The Appointments of Professors Albert Dahan MD, PhD and Tong Joo (TJ) Gan MD, MHS, MBA Highlight a World Class Collection of Medical and Pharmaceutical Industry Experts
PRINCETON, N.J., January 12, 2021 – Enalare Therapeutics Inc., a clinical stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from acute respiratory conditions, announced today that it has completed formation of its scientific advisory board. The Company is very pleased to welcome Albert Dahan MD, PhD, Tong Joo (TJ) Gan MD, Robert Raffa PhD, Eugene Vortsman DO, David Battleman MD, and Alexander Krause PhD to the organization as it advances the development of its lead product ENA-001 for several life-threatening indications involving respiratory depression.
New-york
United-states
Jersey
New-jersey
Long-island
Presbyterian-hospital
Amsterdam
Noord-holland
Netherlands
American
Truenorth-lifesciences
Herm-cukier